Drug Insight: Clopidogrel nonresponsiveness

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 7, 2006, Pages 387-395

  Gurbel, Paul A ^a   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

Clopidogrel; Nonresponsiveness,P2y12 receptors blockers; Platelets; Response variability

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ACETYLSALICYLIC ACID; ATORVASTATIN; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 3A4; ERYTHROMYCIN; HYPERICUM PERFORATUM EXTRACT; PRASUGREL; PURINE P2Y12 RECEPTOR; RECEPTOR BLOCKING AGENT; RIFAMPICIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; HEART INFARCTION; HUMAN; LABORATORY TEST; MAINTENANCE THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

CORONARY THROMBOSIS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 33745562145     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0602     Document Type: Review

References (60)

1. Gurbel PA et al. (2004) Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2: 535-545
2. Tantry US et al. (2005) Resistance to antiplatelet drugs: Current status and future research. Expert Opin Pharmacother 6: 2027-2045
3. 12 receptor in platelet activation. J Clin Invest 113: 340-345
4. 1 antagonist MRS-2179. Cardiovasc Drug Rev 21: 67-76
5. Dorsam RT et al. (2004) Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. J Thromb Haemost 2: 804-812
6. 12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 93: 1128-1136
7. Hermann A et al. (2001) Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12: 74-82
8. Xiao Z and Theroux P (2004) Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 43: 1982-1988
9. Tan KT et al. (2005) Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. Ann Med 37: 61-66
10. Wang K et al. (2005) Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury. Arterioscler Thromb Vasc Biol 25: 1584-1589
11. McFadden EP et al. (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364: 1519-1521
12. Savi P et al. (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72: 313-317
13. Lau WC et al. (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109: 166-171
14. 12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101: 3908-3914
15. Patrono C et al. (2004) Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S234S-S264S
16. Gurbel PA et al. The effect of clopidogrel with and without eptifibatide on tumor necrosis factor-α and C-reactive protein release after elective stenting: Results of the CLEAR PLATELETS-Ib study. J Am Coll Cardiol, in press
17. Di Nisio M et al. (2005) Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes. J Am Coll Cardiol 46: 1582-1583
18. Gurbel PA et al. (2005) Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46: 1820-1826
19. Gurbel PA et al. (2003) Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913
20. Gurbel PA et al. (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45: 1392-1396
21. Yusuf S et al.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502
22. Steinhubl SR et al.; CREDO Investigators (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288: 2411-2420
23. Labarthe B et al. (2005) Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 46: 638-645
24. Matetzky S et al. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109: 3171-3175
25. Gurbel PA et al. (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 46: 1827-1832
26. Ajzenberg N et al. (2005) Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: A case-control study. J Am Coll Cardiol 45: 1753-1756
27. Barragan P et al. (2003) Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59: 295-302
28. Gurbel PA et al. (2005) Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111: 1153-1159
29. Lepantalo A et al. (2004) Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 25: 476-483
30. von Beckerath N et al. (2005) Correlation between platelet response units measured with a point-of-care test and ADP-induced platelet aggregation assessed with conventional optical aggregometry [abstract #P2936]. Presented at the European Society of Cardiology: 2005 September 3-7; Stockholm, Sweden
31. Aleil B et al. (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3: 85-92
32. Cattaneo M (2004) Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24: 1980-1987
33. Jaremo P et al. (2002) Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252: 233-238
34. Muller I et al. (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89: 783-787
35. Mobley JE et al. (2004) Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 93: 456-458
36. Serebruany VL et al. (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45: 246-251
37. Angiolillo DJ et al. (2005) Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115: 101-108
38. Taubert D et al. (2004) Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 92: 311-316
39. von Beckerath N et al. (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112: 2946-2950
40. von Beckerath N et al. (2005) A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost 93: 789-791
41. Lau WC et al. (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 107: 32-37
42. Saw J et al. (2003) Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108: 921-924
43. Wienbergen H et al.; MITRA PLUS Study Group (2003) Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 92: 285-288
44. Gorchakova O et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 25: 1898-1902
45. Lim E et al. (2004) Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial. J Thorac Cardiovasc Surg 128: 432-435
46. Ferroni P et al. (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2: 1282-1291
47. Angiolillo DJ et al. (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54: 2430-2435
48. Angiolillo DJ et al. (2004) Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16: 169-174
49. Beer JH et al. (2000) Genetics of platelet receptor single-nucleotide polymorphisms: Clinical implications in thrombosis. Ann Med 32: 10-14
50. 12 H2 haplotype is associated with peripheral arterial disease: A case-control study. Circulation 108: 2971-2973
51. von Beckerath N et al. (2005) P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 16: 199-204
52. Samara WM et al. (2005) The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 115: 89-94
53. Tantry US et al. (2005) What is the best measure of thrombotic risks - pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? Catheter Cardiovasc Interv 66: 597-598
54. Kastrati A et al. (2004) Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110: 1916-1919
55. Smith SC Jr et al. (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article: A report of American Collage of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113: 156-175
56. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 27: 1038-1047
57. 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151: 689.e1-689.e10
58. 12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111: 3366-3373
59. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339
60. Bhatt DL et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706-1717